Also known as: EC
The European Commission expanded Hympavzi approval to patients 12 and older with hemophilia A or B with inhibitors. Phase 3 data showed a 93% reduction in mean treated annualized bleeding rate versus on-demand therapy.
Rhythm reported Q1 2026 IMCIVREE revenue of $60.1 million and said more than 150 patient start forms were received after U.S. approval in acquired hypothalamic obesity. The company also cited European authorization and a Japanese application under review.
Merck's Enflonsia (clesrovimab) receives EU approval for RSV prevention in infants. Separately, researchers identify a monoclonal antibody cocktail from pediatricians' immune cells that shows potent protection against RSV and hMPV in animal studies.
X4 Pharmaceuticals is on track to complete enrollment of its Phase 3 4WARD trial for mavorixafor in chronic neutropenia by Q3 2026, targeting a 2028 launch. The European Commission approved XOLREMDI for WHIM syndrome, while the company cuts costs and deprioritizes WHIM commercialization.
Novartis received EU approval for Rhapsido (remibrutinib) as the first oral targeted treatment for chronic spontaneous urticaria. Phase 3 data also showed significant efficacy in chronic inducible urticaria, with filings underway for additional indications.
A U.K. focus-group study found support for sharing health data for AI is conditional on public benefit, safeguards and meaningful consent. The findings come as Europe tightens control over biomedical datasets under data-sovereignty policies.
Novartis received a positive CHMP opinion for Itvisma in spinal muscular atrophy patients aged 2 years and older. A European Commission decision is expected within about two months.
The European Commission has launched the Bioeconomy Investment Deployment Group and outlined a €350 million package for food and biotech innovation. The measures target financing gaps that have slowed scale-up from pilot projects to industrial deployment.
VYLOY (zolbetuximab-clzb) remains the only approved CLDN18.2-targeted therapy for first-line HER2-negative gastric or gastroesophageal junction adenocarcinoma with CLDN18.2-positive tumors. The pipeline is focused on next-generation antibodies, ADCs, CAR-T, NK-cell and bispecific approaches aiming to build on zolbetuximab benchmark data.
The European Commission approved Enflonsia for prevention of RSV lower respiratory tract disease in infants during their first RSV season. Merck also reported new Phase 3 SMART data showing generally consistent second-season safety in high-risk children under 2 years old.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07334912 |
AEF0217 in Participants With Down Syndrome |
RECRUITING | PHASE2 |
| NCT07129408 |
Epidemiological Study on the Prevalence of Mental Disorders in Slovakia |
COMPLETED | |
| NCT06897436 |
Characterization of Immune Cells and Their Secreted Cytokines in Endometriosis Patients |
NOT_YET_RECRUITING | |
| NCT06825156 |
Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors |
COMPLETED | PHASE4 |
| NCT06816147 |
HealthyW8_60+ Pilot |
RECRUITING | NA |
| NCT06737744 |
Active Games for Increasing Social and Emotional Competencies of Young Adults in Probation System: a One-Sample Trial Study in Izmir City in Turkiye |
COMPLETED | NA |
| NCT06731244 |
Shared Decision-making Process for Unprovoked vEnous THromboEmbolism Management. (ETHER ) |
RECRUITING | NA |
| NCT06640452 |
RECOVERYFUN: An Integrated VR-based Tele-rehabilitation Platform to Support RECOVERY and Maintenance of FUNctional Abilities Among Seniors |
COMPLETED | NA |
| NCT06605079 |
Enhancing Palliative Care in ICU |
RECRUITING | NA |
| NCT06567054 |
Clinical Study to Predict the Risk of Bone Fractures With the POROUS Ultrasound Device |
RECRUITING | NA |
